| scholarly article | Q13442814 |
| P50 | author | George Fountzilas | Q56432880 |
| P2093 | author name string | Vassiliki Kotoula | |
| Dimitrios Pectasides | |||
| Amanda Psyrri | |||
| Ioannis Varthalitis | |||
| Christos Christodoulou | |||
| Gerasimos Aravantinos | |||
| Ioannis Efstratiou | |||
| Kyriaki Papadopoulou | |||
| Georgios K Glantzounis | |||
| Georgia-Angeliki Koliou | |||
| Christos Poulios | |||
| Kleo Papaparaskeva | |||
| Sofia Chrisafi | |||
| Vasilios Karavasilis | |||
| George Papatsibas | |||
| George K Koukoulis | |||
| Kyriaki Manousou | |||
| Ioannis Tikas | |||
| Elena Fountzilas | |||
| George E Pentheroudakis | |||
| P2860 | cites work | Comprehensive molecular characterization of human colon and rectal cancer | Q24630415 |
| Do multiple outcome measures require p-value adjustment? | Q24796748 | ||
| Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis | Q27024810 | ||
| K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | Q27851454 | ||
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Q27851573 | ||
| Type, density, and location of immune cells within human colorectal tumors predict clinical outcome | Q28131662 | ||
| Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum | Q28262150 | ||
| FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation | Q29616127 | ||
| Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas | Q31081979 | ||
| KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). | Q33693309 | ||
| SPARC, FOXP3, CD8 and CD45 Correlation with Disease Recurrence and Long-Term Disease-Free Survival in Colorectal Cancer | Q33983083 | ||
| BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer | Q34621860 | ||
| Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer | Q34779236 | ||
| Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy | Q34982575 | ||
| p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). | Q35146274 | ||
| Prognostic significance of the allelic loss of the BRCA1 gene in colorectal cancer | Q35596125 | ||
| Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised tri | Q35602966 | ||
| Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage | Q35625752 | ||
| Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803 | Q35729861 | ||
| Prognostic Role of BRAF Mutation in Stage II/III Colorectal Cancer Receiving Curative Resection and Adjuvant Chemotherapy: A Meta-Analysis Based on Randomized Clinical Trials | Q36006605 | ||
| Pten regulates Aurora-A and cooperates with Fbxw7 in modulating radiation-induced tumor development. | Q36071656 | ||
| Better survival in right-sided versus left-sided stage I - III colon cancer patients | Q36087704 | ||
| The consensus molecular subtypes of colorectal cancer | Q36258187 | ||
| ARID1A expression in early stage colorectal adenocarcinoma: an exploration of its prognostic significance. | Q37196672 | ||
| Molecular differences in the microsatellite stable phenotype between left-sided and right-sided colorectal cancer | Q37394567 | ||
| Analysis of histological and immunological parameters of metastatic lymph nodes from colon cancer patients reveals that T-helper 1 type immune response is associated with improved overall survival | Q37409562 | ||
| The emerging roles of ARID1A in tumor suppression | Q38195175 | ||
| Association Between Prognosis and Tumor Laterality in Early-Stage Colon Cancer | Q38736285 | ||
| From tumour heterogeneity to advances in precision treatment of colorectal cancer | Q38786707 | ||
| Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial. | Q38920659 | ||
| Genetic mutations in human rectal cancers detected by targeted sequencing | Q38989186 | ||
| The immune contexture in cancer prognosis and treatment | Q39456999 | ||
| FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression | Q39904718 | ||
| Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. | Q40209192 | ||
| Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas | Q40357176 | ||
| BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer | Q40823445 | ||
| The clinical impact of tumour-infiltrating lymphocytes in colorectal cancer differs by anatomical subsite: A cohort study | Q42359699 | ||
| Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. | Q43924266 | ||
| FBXW7/hCDC4 is a general tumor suppressor in human cancer. | Q45345209 | ||
| Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. | Q46185591 | ||
| Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles | Q46335149 | ||
| BRCA1 and BRCA2 expression patterns and prognostic significance in digestive system cancers | Q47415591 | ||
| Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status | Q47425582 | ||
| Oncogenic Signaling Pathways in The Cancer Genome Atlas | Q52602404 | ||
| Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas | Q52603962 | ||
| Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas | Q52607320 | ||
| Combined assessment of the TNM stage and BRAF mutational status at diagnosis in sporadic colorectal cancer patients. | Q55154129 | ||
| BRAFMutation in Metastatic Colorectal Cancer | Q61481269 | ||
| Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy | Q63883997 | ||
| Tumor Molecular Testing Guides Anti-PD-1 Therapy and Provides Evidence for Pathogenicity of Mismatch Repair Variants | Q90721740 | ||
| P433 | issue | 86 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| P304 | page(s) | 35623-35638 | |
| P577 | publication date | 2018-11-02 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer | |
| P478 | volume | 9 |
Search more.